Fox Run Management L.L.C. Makes New Investment in AxoGen, Inc. (NASDAQ:AXGN)

Fox Run Management L.L.C. bought a new stake in AxoGen, Inc. (NASDAQ:AXGN) during the 4th quarter, Holdings Channel reports. The fund bought 10,269 shares of the medical equipment provider’s stock, valued at approximately $169,000.

Other institutional investors also recently modified their holdings of the company. Quest Partners LLC boosted its stake in AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 2,076 shares during the last quarter. R Squared Ltd bought a new position in shares of AxoGen in the 4th quarter worth $30,000. US Bancorp DE acquired a new stake in shares of AxoGen during the fourth quarter worth $30,000. Harvest Fund Management Co. Ltd bought a new stake in AxoGen in the fourth quarter valued at about $93,000. Finally, Quantbot Technologies LP acquired a new position in AxoGen in the third quarter valued at about $165,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Price Performance

NASDAQ AXGN opened at $18.36 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $21.00. The business has a 50 day simple moving average of $18.27 and a 200 day simple moving average of $15.83. The stock has a market cap of $814.16 million, a price-to-earnings ratio of -57.38 and a beta of 1.02.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AXGN. Lake Street Capital began coverage on AxoGen in a research note on Monday, March 17th. They issued a “buy” rating and a $30.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $24.00 target price on shares of AxoGen in a report on Wednesday, March 5th. Finally, Canaccord Genuity Group boosted their price target on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $22.60.

Insider Transactions at AxoGen

In related news, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the transaction, the director now directly owns 97,899 shares in the company, valued at approximately $1,959,937.98. This trade represents a 4.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Erick Wayne Devinney sold 15,111 shares of AxoGen stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the sale, the insider now directly owns 217,762 shares in the company, valued at approximately $3,810,835. This represents a 6.49 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by insiders.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.